Seer, Inc. SEER
We take great care to ensure that the data presented and summarized in this overview for Seer, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SEER
View all-
Black Rock Inc. New York, NY5.65MShares$10.2 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M05.14MShares$9.3 Million0.05% of portfolio
-
Sb Global Advisers LTD London, X05.14MShares$9.3 Million3.45% of portfolio
-
Artal Group S.A. Luxembourg, N44.75MShares$8.6 Million0.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.64MShares$4.77 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA2.06MShares$3.72 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.33MShares$2.41 Million0.01% of portfolio
-
Citigroup Inc1.26MShares$2.28 Million0.0% of portfolio
-
State Street Corp Boston, MA1.15MShares$2.09 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$1.96 Million0.0% of portfolio
Latest Institutional Activity in SEER
Top Purchases
Top Sells
About SEER
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Insider Transactions at SEER
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2024
|
Robert Langer |
BUY
Grant, award, or other acquisition
|
Direct |
58,178
+6.91%
|
-
|
|
Jun 12
2024
|
Terrance Mcguire |
BUY
Grant, award, or other acquisition
|
Direct |
58,178
+38.85%
|
-
|
|
Jun 12
2024
|
Dipchand Nishar |
BUY
Grant, award, or other acquisition
|
Direct |
58,178
+38.85%
|
-
|
|
Jun 12
2024
|
Rachel E. Haurwitz |
BUY
Grant, award, or other acquisition
|
Direct |
58,178
+39.9%
|
-
|
|
Jun 12
2024
|
Meeta Gulyani |
BUY
Grant, award, or other acquisition
|
Direct |
58,178
+40.06%
|
-
|
|
Jun 12
2024
|
David Hallal |
BUY
Grant, award, or other acquisition
|
Direct |
58,178
+14.08%
|
-
|
|
Mar 07
2024
|
Omid Farokhzad CEO AND CHAIR |
SELL
Open market or private sale
|
Direct |
52,857
-3.55%
|
$105,714
$2.03 P/Share
|
|
Feb 22
2024
|
David R. Horn PRESIDENT & CFO |
SELL
Open market or private sale
|
Direct |
12,684
-2.57%
|
$12,684
$1.58 P/Share
|
|
Feb 22
2024
|
Elona Esq. Kogan CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,684
-4.44%
|
$12,684
$1.58 P/Share
|
|
Feb 06
2024
|
David R. Horn PRESIDENT & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
165,038
+25.07%
|
-
|
|
Feb 06
2024
|
Elona Esq. Kogan CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
123,153
+30.11%
|
-
|
|
Feb 06
2024
|
Omid Farokhzad CEO AND CHAIR |
BUY
Grant, award, or other acquisition
|
Direct |
529,634
+26.24%
|
-
|
|
Feb 05
2024
|
David R. Horn PRESIDENT & CFO |
SELL
Open market or private sale
|
Direct |
3,608
-1.09%
|
$3,608
$1.67 P/Share
|
|
Dec 04
2023
|
Elona Esq. Kogan CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,182
-4.79%
|
$8,182
$1.7 P/Share
|
|
Nov 02
2023
|
Omid Farokhzad CEO AND CHAIR |
BUY
Exercise of conversion of derivative security
|
Direct |
151,764
+13.66%
|
$0
$0.04 P/Share
|
|
Aug 23
2023
|
Omid Farokhzad CEO AND CHAIR |
BUY
Open market or private purchase
|
Direct |
40,000
+4.72%
|
$80,000
$2.45 P/Share
|
|
Jun 14
2023
|
Mostafa Ronaghi Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,443
+9.44%
|
-
|
|
Jun 14
2023
|
Cathy Friedman Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,443
+11.9%
|
-
|
|
Jun 14
2023
|
Meeta Gulyani |
BUY
Grant, award, or other acquisition
|
Direct |
23,443
+44.82%
|
-
|
|
Jun 14
2023
|
David Hallal |
BUY
Grant, award, or other acquisition
|
Direct |
23,443
+7.32%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.17M shares |
|---|---|
| Exercise of conversion of derivative security | 152K shares |
| Open market or private purchase | 40K shares |
| Open market or private sale | 90K shares |
|---|